



**Indivior to Announce Year-to-Date and Q3 2024 Results and Host Webcast on October 24<sup>th</sup>**

**Slough, UK, and Richmond, VA, October 15, 2024** - Indivior PLC (NASDAQ/LSE: INDV) today announced that it will release its year-to-date and Q3 2024 results on October 24<sup>th</sup> at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at [www.indivior.com](http://www.indivior.com).

Mark Crossley, Chief Executive Officer, and other members of Indivior's Leadership team will host a presentation via live webcast at 1:00 p.m. London time (8:00 a.m. U.S. Eastern) on October 24<sup>th</sup>.

**Access to the Live Webcast Presentation:**

The webcast event and materials can be accessed on the "Investors" section of the company's website at [www.indivior.com](http://www.indivior.com) before the event begins.

The webcast link: <https://edge.media-server.com/mmc/p/ppn4ske8>

**Participants may access the presentation telephonically by registering with the following link:**

<https://register.vevent.com/register/Bl4d5b45a6f3e4291ba42150c1620fc64>

*(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)*

A replay of the presentation will be available at [www.indivior.com](http://www.indivior.com).

**About Indivior**

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs approximately 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit [www.indivior.com](http://www.indivior.com) to learn more. Connect with Indivior on LinkedIn by visiting [www.linkedin.com/company/indivior](http://www.linkedin.com/company/indivior).

**Contact:**

Jason Thompson  
Vice President, Investor Relations  
Tel: 804-402-7123 or [jason.thompson@indivior.com](mailto:jason.thompson@indivior.com)

Tim Owens  
Director, Investor Relations  
Tel: 804-263-3978 or [timothy.owens@indivior.com](mailto:timothy.owens@indivior.com)

###



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOREAKELFSFLFFA